Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Uk.ResellerClub Launches New Promotion Offering Free .CO.UK Domains With Hosting Packages

LONDON, May 10, 2013 /PRNewswire/ --  Web Presence products provider Uk.ResellerClub have...

Wirecard Gains SriLankan Airlines As A New Customer In Asia

MUNICH, Germany, April 30, 2013 /PRNewswire/ -- Wirecard AG, provider of a globally accepted payment...

Global Payments Continues Focus On Mobile Payments In The UK

LONDON, March 28, 2013 /PRNewswire/ -- Global Payments is further strengthening its mobile payment...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »


Mundipharma today announced the positive European Commission (EC) decision for flutiform(R) (fluticasone propionate/formoterol fumarate), a new combination therapy for the maintenance treatment of asthma, in Europe. This decision is binding on all 21 Concerned Member States involved in the decentralized procedure (DCP) and the first national approvals of flutiform are expected across a number of countries by the end of 2012. 

 A phase II interferon-free combination study with TMC435 and daclatasvir will evaluate treatment-naive or previous null responder patients with HCV genotype 1a and 1b - The study will include approx. 180 patients and will evaluate a combination of TMC435 and daclatasvir, with or without Ribavirin, in four different cohorts for 12 or 24 weeks of treatment 

 Medivir AB announced that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July. 

 In a head-to-head trial between VPRIV and Cerezyme(R) (imiglucerase), only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density at 9 months 

 Shire plc today presented new data that show VPRIV(R) (velaglucerase alfa for injection), the company's enzyme replacement therapy for type 1 Gaucher disease, significantly improved selected markers of Gaucher-related bone disease in patients. These data were presented at the European Working Group on Gaucher Disease (EWGGD) meeting held in Paris, France. 

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of subcutaneous (under the skin) administration of VELCADE(R) (bortezomib). VELCADE(R) is indicated for the treatment of multiple myeloma, a type of blood cancer. Subcutaneous bortezomib has fewer side effects and offers greater convenience for patients, with similar efficacy compared to intravenous bortezomib. VELCADE(R) plays a central role in effectively managing multiple myeloma across different patient types and lines of therapy.[1,2] 

Abbott announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HUMIRA (adalimumab) in adults with severe axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage. Upon final decision from the European Commission, HUMIRA will be the first and only approved medication available for non-radiographic axSpA patients (nr-axSpA).

Takeda Pharmaceutical Company Limited and AMAG Pharmaceuticals, Inc. today announced the granting of marketing authorization by the European Commission (EC) for ferumoxytol, a new intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). The marketing authorization follows a positive opinion issued on April 19, 2012, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).